Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer
Author:
Funder
Roche
Publisher
Elsevier BV
Subject
Gastroenterology,Oncology
Reference24 articles.
1. Canadian Cancer Statistics 2014,2014
2. Colorectal liver metastases;Tzeng;J Gastrointest Surg,2013
3. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience;Shimizu;Int J Clin Oncol,2007
4. The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (CAPOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (CAPOXA);Schmoll;J Clin Oncol,2012
5. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial;Madi;Br J Cancer,2012
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review;Cost Effectiveness and Resource Allocation;2023-01-31
2. Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer;BMC Cancer;2022-06-18
3. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer;Clinical Colorectal Cancer;2018-06
4. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study;Journal of Oncology Pharmacy Practice;2017-07-16
5. Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia;Generics and Biosimilars Initiative Journal;2016-12-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3